- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Milind Desai Addresses Late-breaking VALOR-HCM Trial Findings at ACC 2022
Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.
The myosin inhibitor mavacamten is the first therapy to show long-term reduction in gradient, improvement in quality of life, and improvement in functional capacity in the treatment of hypertrophic cardiomyopathy (HCM), said Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, at Cleveland Clinic.
Transcript
How are emerging pharmacological options for obstructive hypertrophic cardiomyopathy advancing treatment of the disease compared with established drugs?
Established drugs were never developed for specific management of HCM. In fact, I will tell you, earlier this year in 2022 or maybe late 2021, there was a paper published in Journal of the American College of Cardiology looking at a small group of patients randomized to beta-blockers vs not, and that showed that it reduces gradient, but it did not show an improvement in functional capacity. All it showed was reduction in gradient.
This small prospective study is one of the 2 that I know, of prospective studies. The last prospective study on a beta-blocker was developed in the late 60s, early 70s, and that was also in a handful of patients. There is no prospective trial on calcium-channel blockers. There is no prospective trial on disopyramide.
Essentially, the previous data, as a serendipity, is how we have started using the other drugs. The myosin inhibitors is the first therapy that has been tested in a randomized control trial in a multicenter format, with a long-term extension arm that has shown reduction in gradient, improvement in quality of life, and improvement in functional capacity.
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
